The enablers of the “one-size-fits-many” blockbuster model are eroding. Payers are pushing back more aggressively on “me-too” treatments where value can’t be demonstrated. With consolidation and greater pressure to manage cost and quality, hospital administrators now exert greater influence over clinicians’ prescribing decisions.

There’s great value in smaller, more targeted patient populations – but finding it demands new approaches. Numerof President Rita Numerof, PhD identifies some of the key requirements for success in Market Segmentation in the New Healthcare Landscape, published recently by eyeforpharma.

Read More